There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
Cross-Coupling of Primary Amides to Aryl and Heteroaryl Partners Using (DiMeIHept<sup>Cl</sup>)Pd Promoted by Trialkylboranes or B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>
作者:Sepideh Sharif、Jonathan Day、Howard N. Hunter、Yu Lu、David Mitchell、Michael J. Rodriguez、Michael G. Organ
DOI:10.1021/jacs.7b09488
日期:2017.12.27
the coupling of amide nucleophiles to a wide variety of oxidativeadditionpartners using Pd-NHC catalysts. Through a combination of NMR spectroscopy and control studies with and without oxygen and radical scavengers, we propose that boron-imidates form under the basic reaction conditions that aid coordination of nitrogen to Pd(II), which is rate limiting, and directly delivers the intermediate for reductive
activity in various solvents under mild conditions and showed excellent stability. The catalytic performance was also evaluated in the one‐pot reduction of nitroaromatics and amidation with carboxylicacids under a hydrogen atmosphere at 100 °C. These methods for the hydrogenation of nitroaromatics and the direct amidation of nitroaromatics with carboxylicacids are simple, economical, and environmentally
Organocatalytic, Enantioselective Reductive Bis-functionalization of Secondary Amides: One-Pot Construction of Chiral 2,2-Disubstituted 3-Iminoindoline
We report the first catalytic, enantioselectivereductive bis-functionalization of common amides, which provides a facile access to a variety of 2,2-disubstituted 3-iminoindolines in good yields and with excellent enantioselectivities. The reaction conditions are quite mild and can be run on a gram scale. In this one-pot reaction, three C-C bonds, one ring, and one nitrogen-containing tetrasubstituted
ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:US20130143843A1
公开(公告)日:2013-06-06
The present invention provides compounds of Formula (I):
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.